EDIT vs. UL

Last updated Jun 13, 2026

EDIT (Editas Medicine, Inc.) and UL (The Unilever Group) are both stocks. EDIT operates in Biotechnology (Healthcare), while UL operates in Household & Personal Products (Consumer Defensive). Over the past 10 years, EDIT returned -22.22%/yr vs 5.33%/yr for UL. At a 0.10 correlation, their price movements are largely independent.

Performance

EDIT vs. UL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and The Unilever Group (UL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, EDIT achieves a 21.95% return, which is significantly higher than UL's -8.35% return. Over the past 10 years, EDIT has underperformed UL with an annualized return of -22.22%, while UL has yielded a comparatively higher 5.33% annualized return.

EDIT

• 1D: 2.46%
• 1M: -4.58%
• YTD: 21.95%
• 6M: -1.19%
• 1Y: 26.90%
• 3Y*: -39.82%
• 5Y*: -41.79%
• 10Y*: -22.22%

UL

• 1D: 1.03%
• 1M: 4.77%
• YTD: -8.35%
• 6M: -7.70%
• 1Y: -13.60%
• 3Y*: 5.05%
• 5Y*: 0.66%
• 10Y*: 5.33%

*Multi-year figures are annualized to reflect compound growth (CAGR)

EDIT vs. UL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EDIT Editas Medicine, Inc.	21.95%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%
UL The Unilever Group	-8.35%	5.96%	20.90%	-0.17%	-2.82%	-7.61%	9.04%	12.88%	-2.34%	40.15%

Correlation

The correlation between EDIT and UL is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.11
Correlation (5Y) Calculated over the trailing 5-year period	0.12
Correlation (10Y) Calculated over the trailing 10-year period	0.10
Correlation (All Time) Calculated using the full available price history since Feb 3, 2016	0.10

Fundamentals

Market Cap EDIT : $244.70M UL : $129.35B
EPS EDIT : -$1.21 UL : €5.06
PS Ratio EDIT : 6.29 UL : 1.09
PB Ratio EDIT : 55.51 UL : 7.20
Total Revenue (TTM) EDIT : $35.86M UL : €109.27B
Gross Profit (TTM) EDIT : $35.86M UL : €90.89B
EBITDA (TTM) EDIT : -$76.66M UL : €24.12B

Return for Risk

EDIT vs. UL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT

EDIT Risk / Return Rank: 51
EDIT Sharpe Ratio Rank: 48
EDIT Sortino Ratio Rank: 56
EDIT Omega Ratio Rank: 53
EDIT Calmar Ratio Rank: 49
EDIT Martin Ratio Rank: 48

UL

UL Risk / Return Rank: 16
UL Sharpe Ratio Rank: 13
UL Sortino Ratio Rank: 14
UL Omega Ratio Rank: 15
UL Calmar Ratio Rank: 21
UL Martin Ratio Rank: 15

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EDIT vs. UL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and The Unilever Group (UL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	EDIT	UL	Difference
Sharpe ratio: Return per unit of total volatility	0.16	-0.70	+0.85
Sortino ratio: Return per unit of downside risk	0.98	-0.87	+1.85
Omega ratio: Gain probability vs. loss probability	1.11	0.90	+0.22
Calmar ratio: Return relative to maximum drawdown	0.25	-0.60	+0.84
Martin ratio: Return relative to average drawdown	0.43	-1.23	+1.66

EDIT vs. UL - Sharpe Ratio Comparison

The current EDIT Sharpe Ratio is 0.16, which is higher than the UL Sharpe Ratio of -0.70. The chart below compares the historical Sharpe Ratios of EDIT and UL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

EDIT vs. UL - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, which is greater than UL's maximum drawdown of -53.55%. Use the drawdown chart below to compare losses from any high point for EDIT and UL.

Drawdown Indicators

	EDIT	UL	Difference
Max Drawdown Largest peak-to-trough decline	-98.92%	-53.55%	-45.37%
Max Drawdown (1Y) Largest decline over 1 year	-59.88%	-25.09%	-34.79%
Max Drawdown (3Y) Largest decline over 3 years	-91.18%	-25.09%	-66.09%
Max Drawdown (5Y) Largest decline over 5 years	-98.66%	-26.53%	-72.13%
Max Drawdown (10Y) Largest decline over 10 years	-98.92%	-30.13%	-68.79%
Current Drawdown Current decline from peak	-97.24%	-19.64%	-77.60%
Average Drawdown Average peak-to-trough decline	-62.63%	-10.61%	-52.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.03%	12.20%	+21.83%

Volatility

EDIT vs. UL - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 32.34% compared to The Unilever Group (UL) at 6.11%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than UL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EDIT	UL	Difference
Volatility (1M) Calculated over the trailing 1-month period	32.34%	6.11%	+26.23%
Volatility (6M) Calculated over the trailing 6-month period	61.63%	16.78%	+44.85%
Volatility (1Y) Calculated over the trailing 1-year period	94.75%	21.50%	+73.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.12%	20.87%	+73.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.80%	21.61%	+62.19%

Dividends

EDIT vs. UL - Dividend Comparison

EDIT has not paid dividends to shareholders, while UL's dividend yield for the trailing twelve months is around 3.87%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
EDIT Editas Medicine, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
UL The Unilever Group	3.87%	3.51%	3.29%	3.83%	3.57%	3.77%	3.07%	3.18%	3.49%	2.80%	3.42%	3.02%

Financials

Frequently Asked Questions

Can I hold both EDIT and UL in my portfolio?

EDIT and UL have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, EDIT or UL?

EDIT has higher volatility (32.34%) compared to UL (6.11%). In terms of maximum drawdown, EDIT dropped -98.92% vs UL's -53.55%.

Which has better risk-adjusted returns?

EDIT currently has the higher Sharpe Ratio (0.16 vs -0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.